Outcomes in COVID-19 hesperidin studies

0 0.5 1 1.5+ All studies -209% 1 211 Improvement, Studies, Patients Relative Risk RCTs -209% 1 211 Early -209% 1 211 Hesperidin for COVID-19 c19early.org November 2025 Favorshesperidin Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dupuis (DB RCT) -209% 3.09 [0.33-29.2] progression 3/104 1/107 Improvement, RR [CI] Treatment Control Okasha (DB RCT) unknown, >5 years late 100 (est. total) Tau​2 = 0.00, I​2 = 0.0%, p = 0.33 Early treatment -209% 3.09 [0.33-29.2] 3/104 1/107 209% higher risk All studies -209% 3.09 [0.33-29.2] 3/104 1/107 209% higher risk 1 hesperidin COVID-19 study (+1 unreported RCT) c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.33 Effect extraction pre-specified(most serious outcome) Favors hesperidin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dupuis (DB RCT) -209% 3.09 [0.33-29.2] progression 3/104 1/107 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.33 Early treatment -209% 3.09 [0.33-29.2] 3/104 1/107 209% higher risk All studies -209% 3.09 [0.33-29.2] 3/104 1/107 209% higher risk 1 hesperidin COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.33 Effect extraction pre-specified(most serious outcome) Favors hesperidin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dupuis (DB RCT) 31% 0.69 [0.38-1.27] no recov. 104 (n) 107 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Early treatment 31% 0.69 [0.38-1.27] 104 (n) 107 (n) 31% lower risk All studies 31% 0.69 [0.38-1.27] 104 (n) 107 (n) 31% lower risk 1 hesperidin COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.23 Favors hesperidin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dupuis (DB RCT) -209% 3.09 [0.33-29.2] progression 3/104 1/107 Improvement, RR [CI] Treatment Control Okasha (DB RCT) unknown, >5 years late 100 (est. total) Tau​2 = 0.00, I​2 = 0.0%, p = 0.33 Early treatment -209% 3.09 [0.33-29.2] 3/104 1/107 209% higher risk All studies -209% 3.09 [0.33-29.2] 3/104 1/107 209% higher risk 1 hesperidin COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.33 Effect extraction pre-specified(most serious outcome) Favors hesperidin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dupuis (DB RCT) -209% 3.09 [0.33-29.2] progression 3/104 1/107 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.33 Early treatment -209% 3.09 [0.33-29.2] 3/104 1/107 209% higher risk All studies -209% 3.09 [0.33-29.2] 3/104 1/107 209% higher risk 1 hesperidin COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.33 Effect extraction pre-specified(most serious outcome) Favors hesperidin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Dupuis (DB RCT) -209% 3.09 [0.33-29.2] progression 3/104 1/107 Improvement, RR [CI] Treatment Control Dupuis (DB RCT) 31% 0.69 [0.38-1.27] no recov. 104 (n) 107 (n) Hesperidin COVID-19 outcomes c19early.org November 2025 Favors hesperidin Favors control